And the results held throughout the 52 weeks
Evaluations should be conducted across various clinical trial phases-including Phase I, Phase II, Phase IIb, and Phase III-to tailor antioxidant therapies to specific disease subtypes, ranging from simple antioxidant interventions to combination therapies
Similarly, major cardiovascular outcome trialsincluding LEADER (liraglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), and REWIND (dulaglutide)reported pancreatic cancer incidence rates that were comparable between treatment and placebo groups
(120(1)):217-224 doi:10.1016/j.ajcnut.2024.05.019
G.Di MarzoV
Headaches are among the commonly reported side effects during the initial treatment phase, with frequency varying between different GLP-1 medicines according to their Summary of Product Characteristics